Clinical study on the recombinant human endostatin regarding improving the blood perfusion and hypoxia of non-small-cell lung cancer
Clin. transl. oncol. (Print)
; 14(6): 437-443, jun. 2012.
Artigo
em Inglês
| IBECS
| ID: ibc-126812
Biblioteca responsável:
ES1.1
Localização: BNCS
ABSTRACT
OBJECTIVE:
To observe the dynamic changes of blood perfusion and hypoxic status with CT perfusion imaging and hypoxia imaging in patients of non-small-cell lung cancer (NSCLC) who were treated with recombinant human endostatin (RHES).METHODS:
Fifteen previously untreated patients with histologically or cytologically confirmed NSCLC were enrolled. They were randomly divided into research group (n=10) and negative control group (n=5). The patients of the research group continuously used RHES for ten days, and simultaneously had CT perfusion imaging and hypoxia imaging performed on days 1, 5 and 10, respectively. The remaining 5(control) only had CT perfusion imaging and hypoxia imaging, without using RHES, on days 1, 5 and 10, respectively. According to the above results, we could obtain a "time window" during which RHES improves blood perfusion and hypoxia of lung cancer.RESULTS:
In the research group, after using RHES, capillary permeability surface (PS) and tumour to normal tissue (T/N) decreased at first, and then increased. Their lowest points occurred on about the fifth day with statistical significance compared with the first day (T/N, p=0.00; PS, p<0.01). Blood flow (BF) was first increased and then decreased. Its highest point occurred on about the fifth day with statistical significance compared with the first and tenth day (all p<0.01). The PS, BF and T/N peaked on the fifth day in the research group with statistical significance compared with the negative control group as well (all p<0.01). The above results suggested that RHES's "time window" was within about one week after administration. ¡CONCLUSION:
RHES's "time window" is within about one week after administration, which provides an important experimental basis for combining RHES with radiotherapy in human tumours (AU)
Buscar no Google
Coleções:
Bases de dados nacionais
/
Espanha
Base de dados:
IBECS
Assunto principal:
Carcinoma Pulmonar de Células não Pequenas
/
Inibidores da Angiogênese
/
Endostatinas
/
Neoplasias Pulmonares
Tipo de estudo:
Ensaio clínico controlado
Limite:
Feminino
/
Humanos
/
Masculino
Idioma:
Inglês
Revista:
Clin. transl. oncol. (Print)
Ano de publicação:
2012
Tipo de documento:
Artigo
Instituição/País de afiliação:
Lianyungang First People's Hospital/China